| INTRODUCTION
Atypical vascular lesions (AVL) and angiosarcomas (AS) are radiationinduced, vascular proliferations that arise mostly on irradiated skin of breast cancer patients. It is important to distinguish AVL from AS histologically because they have a different clinical course and hence distinctly different management. The occurrence of these lesions is rare but appears to be increasing possibly due to frequent use of radiation in the setting of conservative surgical therapy for early stage breast carcinomas. 1, 2 This increase could also be in part due to the increased awareness among oncologists, dermatologists, and pathologists. In contrast to AVL, which can develop after radiation in both total or segmental mastectomy (lumpectomy, ie, breast conserving surgical therapy), post-radiation AS develops predominantly in the latter setting.
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| Atypical vascular lesions
The term AVL was first applied by Fineberg and Rosen in a case series from 1994. 5 They described four cases of AVL arising on irradiated skin following conservative treatment for breast carcinoma. Lately, AVLs have also been described in other locations such as scalp and larynx, following radiation therapy for hypothalamic pilocytic astrocytoma and squamous cell carcinoma, respectively. 6, 7 AVLs are believed to arise as a consequence of lymphatic obstruction following radiotherapy and/or surgery, causing dilatation of superficial vascular channels. 8, 9 Recent data show that the incidence of these lesions is similar after radiation in patients that underwent either breast-conserving therapy or total mastectomy. 1, 10 AVLs occur most commonly in patients in their late 50s and develop 3 to 4 years after radiotherapy. 3, 8, 11 AVLs present clinically as solitary or multiple small, circumscribed, reddish brown papules that usually measure less than 5 mm in diameter. 1, 3, 8 Infrequently, the lesions can grow up to 20 mm. 10 The clinical differential diagnosis includes recurrence of breast carcinoma, post-traumatic hemorrhage, and benign dermatologic conditions. 3, 12 Although the clinical outcome of AVL is mostly favorable, rare cases of AS have been reported to develop in association with AVL. 4, 8, 10 Complete excision and close follow-up is the treatment of choice; however, this may not always be practical in patients with multiple AVLs. 3, 8 A closely related condition, benign lymphangiomatous papule (BLAP) has also been described, which is another rare benign lesion that may result from radiation exposure to the breast. 16 Clinically BLAP are flesh-colored and hyperpigmented papules that display a similar histology as AVL but do not show infiltration into the deep dermis or subcutis. We believe that BLAP is part of the spectrum of these benign vascular lesions and represents another manifestation of AVL.
Microscopically, AVL are relatively circumscribed, symmetrical, and often wedge-shaped collections of dilated lymphovascular channels, located in the superficial to mid dermis and rarely extending into the deep dermis or the subcutis ( Figure 1A ). The vessels are lined by a single layer of endothelial cells that are monomorphous, with flattened, plump or hobnail-like morphology and hyperchromatic nuclei ( Figure 1B) . 5, 8 The vessels are typically thin-walled, ectatic or narrow, with irregular, angulated profiles, and focal anastomoses. There are commonly thin projections of endothelium-covered stroma into the lumen ( Figure 1C lowing radical mastectomy and axillary lymph node dissection. 17 The incidence of this tumor appears to be decreasing since more women undergo breast-conservative treatment (segmental/partial mastectomy, radiation, adjuvant chemotherapy, and sentinel lymph node biopsy). The relative risk of post-radiation AS, on the other hand, is increasing, but still the incidence is low, estimated to be 0.05% to 1.11%. 1, 3, 10 Primary breast AS occurs at a median age of 70 years, which is more than a decade later than AVL. Post-radiation angiosarcomas develop~5-6 years after radiation therapy, but the range varies from 1 year up to several decades, and the lesions are known to occur following a much shorter interval than other radiationinduced sarcomas. 18, 19 Although the median latency for the development of AS is longer than AVL, the radiation dose appears to be similar. 1 AS presents clinically as large, painless, often multifocal erythematous plaques, hemorrhagic patches, or tumor nodules measuring several centimeters (up to 20 cm). 1, 3, 10 They can also appear as bruiselike discoloration overlying a painless area of induration. The previous surgical scar is almost always involved. 3 The clinical differential diagnoses of AS is similar to AVL including recurrence of the breast carcinoma, hemorrhage, and other dermatological conditions.
3,12
The histologic spectrum of post-radiation angiosarcoma ranges from well-differentiated to poorly differentiated tumors. Microscopically, well-differentiated angiosarcoma shows anastomosing vascular channels that are ill-defined and diffusely dissect the dermal colla- A recent study showed that a subtle histologic presentation of AS can mimic the changes seen in chronic radiation dermatitis. 23 The single hyperchromatic cells in the background of collagen seen in some cases of well-differentiated AS appears similar to the atypical fibroblasts scattered singly in the background of thickened collagen bundles seen in chronic radiation dermatitis.
The presence of hemorrhage in association with the scattered Table 1) . A helpful finding favoring angiosarcoma is the presence of endothelial cells "floating" in the middle of vascular lumina, apparently detached from vessel wall (so-called promontory sign). 25 Distinction between a well-differentiated angiosarcoma and an AVL can sometimes be quite challenging, particularly on small shave biopsies. Subtle differences between the two includes a greater degree of cytologic atypia in angiosarcoma vs AVL, increase in the number and density of the vascular elements, with frequent and well-developed anastomosing vascular channels and diffuse permeation of adnexa and subcutaneous fat by the proliferating vessels, which may not be readily obvious on small superficial biopsies. In equivocal cases, small biopsies may need to be signed out as "consistent with atypical vascular proliferation; a well-differentiated angiosarcoma cannot be ruled out."
The proliferation index is higher (>20%) in AS than in AVL, and thus, Ki67 may be helpful in this differential diagnosis in small biopsies ( Figure 5A ,B) 8 . However, it is important to note that Ki67 can also be low in well-differentiated angiosarcoma and therefore this stain can be misleading for well-differentiated vascular tumors. Furthermore, it has been suggested that AVL with high Ki67 may have a higher probability to develop AS. MYC is a proto-oncogene that regulates several genes by encoding a helix-loop-helix leucine zipper transcription factor, and can be amplified in secondary AS, 27 Some studies have suggested the use of Prox-1, a homeobox gene that plays an important role in differentiation of lymphatic vessels and represents a master gene that is involved in re-programming of blood vessels into lymphatic endothelial cells. 34 Mentzel et al showed the presence of prox-1 in all cases of post-radiation cutaneous angiosarcoma, on the other hand AVLs showed only focal positive stain for prox-1 in few cases. 29 Recently, Mentzel et al also showed that there is a loss of H3K27me3 (histone H3K27 trimethylation) expression in most cases of radiation associated AS while endothelial cells in AVL preserve expression of H3K27me3. 35 This finding may be another potential diagnostic tool for identifying secondary AS.
Regarding clinical behavior and prognosis, post-radiation AS has a high rate of local recurrence and, less frequently, distant metastases despite wide surgical excision. 1, 3, 10 Metastatic sites include the lung, contralateral breast, skeleton, lymph nodes, liver, and soft tissue. 3, 5, 30 The median survival of these patients is 18 months. 3 Size over 5 cm of the primary tumor is a significant predictor of overall survival but the impact of histologic grade has been controversial. 3, 5, 10 The current treatment of choice is radical mastectomy with wide surgical margins.
Chemotherapy can improve the outcome in metastatic disease. 
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